153 related articles for article (PubMed ID: 37079976)
1. Tumour microenvironment and aberrant signaling pathways in cisplatin resistance and strategies to overcome in oral cancer.
Biswal S; Panda M; Sahoo RK; Tripathi SK; Biswal BK
Arch Oral Biol; 2023 Jul; 151():105697. PubMed ID: 37079976
[TBL] [Abstract][Full Text] [Related]
2. Cell signaling and cancer: a mechanistic insight into drug resistance.
Panda M; Biswal BK
Mol Biol Rep; 2019 Oct; 46(5):5645-5659. PubMed ID: 31280421
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-218 promotes cisplatin resistance in oral cancer via the PPP2R5A/Wnt signaling pathway.
Zhuang Z; Hu F; Hu J; Wang C; Hou J; Yu Z; Wang TT; Liu X; Huang H
Oncol Rep; 2017 Oct; 38(4):2051-2061. PubMed ID: 28849187
[TBL] [Abstract][Full Text] [Related]
4. Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3β signaling networks promotes chemoresistance, invasion/migration and stemness via expression of CD44 variants (v4 and v6) in oral cancer.
Kashyap T; Pramanik KK; Nath N; Mishra P; Singh AK; Nagini S; Rana A; Mishra R
Oral Oncol; 2018 Nov; 86():234-243. PubMed ID: 30409306
[TBL] [Abstract][Full Text] [Related]
5. Association of the Epithelial-Mesenchymal Transition (EMT) with Cisplatin Resistance.
Ashrafizadeh M; Zarrabi A; Hushmandi K; Kalantari M; Mohammadinejad R; Javaheri T; Sethi G
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32503307
[TBL] [Abstract][Full Text] [Related]
6. Effect of combining epidermal growth factor receptor inhibitors and cisplatin on proliferation and apoptosis of oral squamous cell carcinoma cells.
Takaoka S; Iwase M; Uchida M; Yoshiba S; Kondo G; Watanabe H; Ohashi M; Nagumo M; Shintani S
Int J Oncol; 2007 Jun; 30(6):1469-76. PubMed ID: 17487368
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin induces the release of extracellular vesicles from ovarian cancer cells that can induce invasiveness and drug resistance in bystander cells.
Samuel P; Mulcahy LA; Furlong F; McCarthy HO; Brooks SA; Fabbri M; Pink RC; Carter DRF
Philos Trans R Soc Lond B Biol Sci; 2018 Jan; 373(1737):. PubMed ID: 29158318
[TBL] [Abstract][Full Text] [Related]
8. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis.
Mohapatra P; Shriwas O; Mohanty S; Ghosh A; Smita S; Kaushik SR; Arya R; Rath R; Das Majumdar SK; Muduly DK; Raghav SK; Nanda RK; Dash R
JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33434185
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of ABCG2 via the PI3K-Akt pathway contributes to acidic microenvironment-induced cisplatin resistance in A549 and LTEP-a-2 lung cancer cells.
Hu CF; Huang YY; Wang YJ; Gao FG
Oncol Rep; 2016 Jul; 36(1):455-61. PubMed ID: 27221310
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a.
Cheng C; Qin Y; Zhi Q; Wang J; Qin C
Int J Biol Macromol; 2018 Feb; 107(Pt B):2620-2629. PubMed ID: 29080815
[TBL] [Abstract][Full Text] [Related]
11. Label-free-based quantitative proteomic analysis of the inhibition of cisplatin-resistant ovarian cancer cell proliferation by cucurbitacin B.
Yin S; Mai Z; Liu C; Xu L; Xia C
Phytomedicine; 2023 Mar; 111():154669. PubMed ID: 36681055
[TBL] [Abstract][Full Text] [Related]
12. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.
Fu X; Feng J; Zeng D; Ding Y; Yu C; Yang B
Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919028
[TBL] [Abstract][Full Text] [Related]
13. Long noncoding RNA DANCR mediates cisplatin resistance in glioma cells via activating AXL/PI3K/Akt/NF-κB signaling pathway.
Ma Y; Zhou G; Li M; Hu D; Zhang L; Liu P; Lin K
Neurochem Int; 2018 Sep; 118():233-241. PubMed ID: 29572052
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of Cisplatin Resistance in HPV Negative Head and Neck Squamous Cell Carcinomas.
Griso AB; Acero-Riaguas L; Castelo B; Cebrián-Carretero JL; Sastre-Perona A
Cells; 2022 Feb; 11(3):. PubMed ID: 35159370
[TBL] [Abstract][Full Text] [Related]
15. c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2.
Tang MK; Zhou HY; Yam JW; Wong AS
Neoplasia; 2010 Feb; 12(2):128-38. PubMed ID: 20126471
[TBL] [Abstract][Full Text] [Related]
16. Cellular landscaping of cisplatin resistance in cervical cancer.
Bhattacharjee R; Dey T; Kumar L; Kar S; Sarkar R; Ghorai M; Malik S; Jha NK; Vellingiri B; Kesari KK; Pérez de la Lastra JM; Dey A
Biomed Pharmacother; 2022 Sep; 153():113345. PubMed ID: 35810692
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
Wu D; Lu P; Mi X; Miao J
Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
[TBL] [Abstract][Full Text] [Related]
18. PAK4 confers the malignance of cervical cancers and contributes to the cisplatin-resistance in cervical cancer cells via PI3K/AKT pathway.
Shu XR; Wu J; Sun H; Chi LQ; Wang JH
Diagn Pathol; 2015 Sep; 10():177. PubMed ID: 26411419
[TBL] [Abstract][Full Text] [Related]
19. PD-1/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K/AKT mediated P-gp expression.
Wu L; Cai S; Deng Y; Zhang Z; Zhou X; Su Y; Xu D
Int Immunopharmacol; 2021 May; 94():107443. PubMed ID: 33581579
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
Gohr K; Hamacher A; Engelke LH; Kassack MU
BMC Cancer; 2017 Nov; 17(1):711. PubMed ID: 29100507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
